HER2-positive metastatic gastric / cardioesophageal junction cancer: a comparative retrospective analysis of trastuzumab maintenance therapy regimens
R. Sh. Abdulaeva,
E. Yu. Timofeeva,
E. S. Obarevich,
D. A. Gavrilova,
N. S. Besova,
G. G. Makiev,
A. A. Tryakin,
V. I. Evdokimov,
I. A. Pokataev,
L. G. Zhukova,
A. S. Danilova,
M. Yu. Fedyanin,
S. V. Cheporov,
M. A. Osipov,
V. V. Molodorina https://doi.org/10.33667/2078-5631-2025-33-7-12
Abstract
Objective. To evaluate the efficacy and safety of different maintenance therapy regimens in patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Materials and methods. This retrospective analysis included data from 186 patients who received trastuzumab in combination with platinum-fluoropyrimidine chemotherapy. During the maintenance phase, patients were divided into two groups: trastuzumab monotherapy and trastuzumab plus fluoropyrimidines.
Results. No significant differences were observed between the groups in overall survival (OS) or progression-free survival (PFS) (OS: 26.0 vs 24.0 months; PFS: 13.5 vs 13.1 months; p>0.05). Combination therapy was associated with a higher incidence of toxicity, including hand–foot syndrome (19.4 % vs 0.8 %) and cardiotoxicity (11.3 % vs 3.2 %).
Conclusion. The continuation of fluoropyrimidines during the maintenance phase does not improve treatment efficacy and increases toxicity. The optimal strategy remains prolonged HER2 blockade with trastuzumab.
About the Authors
R. Sh. Abdulaeva
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
oncologist at Dept of Antitumor Drug Therapy No. 2 of Dept of Drug Treatment Methods of N. N. Trapeznikov Research Institute of Cancer Treatment
Moscow
E. Yu. Timofeeva
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
resident physician
Moscow
E. S. Obarevich
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
oncologist
Moscow
D. A. Gavrilova
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
oncologist
Moscow
N. S. Besova
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
PhD Med, leading researcher, oncologist
Moscow
G. G. Makiev
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
oncologist
Moscow
A. A. Tryakin
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Dr Med Sci (habil.), professor, deputy director for Research (Research Institute of Oncology) and head of Dept of Antitumor Drug Therapy No. 2, oncologist
Moscow
V. I. Evdokimov
Moscow Multidisciplinary Clinical Center «Kommunarka»
Russian Federation
Russian Federation
oncologist, head of the Outpatient Oncology Care Center
Moscow, Kommunarka
I. A. Pokataev
Branch of the Oncology Center No. 1 of the S. S. Yudin City Clinical Hospital
Russian Federation
Russian Federation
Dr Med Sci (habil.), head of the Chemotherapy Treatment Service
Moscow
L. G. Zhukova
A. S. Loginov Moscow Clinical Scientific and Practical Center
Russian Federation
Russian Federation
Dr Med Sci (habil.), RAS corresponding member, deputy director for Research
Moscow
A. S. Danilova
Moscow City Oncology Hospital No. 62
Russian Federation
Russian Federation
PhD Med, oncologist, head of Day Hospital Dept
Moscow
M. Yu. Fedyanin
N. N. Blokhin National Medical Research Center of Oncology;
Moscow Multidisciplinary Clinical Center «Kommunarka»
Russian Federation
Russian Federation
Dr Med Sci (habil.), professor, head of the Chemotherapy Treatment Service; senior researcher at Specialized Outpatient Clinical Oncology Dept No. 2 of N. N. Trapeznikov Research Institute of Clinical Oncology
Moscow; Moscow, Kommunarka
S. V. Cheporov
Yaroslavl Regional Clinical Oncology Hospital; Yaroslavl State Medical University
Russian Federation
Russian Federation
PhD Med, associate professor; head of Dept
AuthorID: 723405.
ResearcherID Web of Science GLT-0576-2022.
Yaroslavl
M. A. Osipov
Nizhny Novgorod Regional Clinical Oncology Dispensary
Russian Federation
Russian Federation
PhD Med, head of Chemotherapy Dept No. 4
Nizhny Novgorod
V. V. Molodorina
Kaliningrad Region Oncology Center
Russian Federation
Russian Federation
oncologist at Budgetary Health Care institution
Rodniki, Kaliningrad Region
References
1. Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024. 74 (3): p. 229–263.
2. Van Cutsem, E., et al., HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer, 2015. 18 (3): p. 476–84.
3. Kawakami, T. and K. Yamazaki, Recent Progress in Treatment for HER2-Positive Advanced Gastric Cancer. Cancers (Basel), 2024. 16 (9).
4. Bang, Y.J., et al., Trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 trial. Lancet, 2010. 376 (9742): p. 687–697.
5. ESMO Clinical Practice Guidelines: Gastric cancer. Ann Oncol, 2022. 33(10): p. 1005–1020.
6. National Comprehensive Cancer, N., NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2025. 2025.
7. Russian Society of Clinical, o., Practical recommendations: Gastric cancer (version 2024). 2024. (In Russ.).
8. Bergen, E.S., et al., Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma (AGEO study). Gastric Cancer, 2023.
9. Gürbüz, M., et al., Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Real-World Data of the Turkish Oncology Group. Journal of Gastrointestinal Cancer, 2021. 53 (2): p. 282–288.
10. Pietrantonio, F., et al., Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer (VALENTINO): A Phase 2 Randomized Clinical Trial. JAMA Oncology, 2019. 5 (9): p. 1268–1275.
11. Modest, D.P., et al., Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer (PANAMA; AIO KRK-0212): A Randomized Trial. Journal of Clinical Oncology, 2022. 40 (1): p. 72–82.
12. Li, Q., et al., A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. J Cancer Res Clin Oncol, 2020. 146 (1): p. 287–295.
Review
For citations:
Abdulaeva R.Sh., Timofeeva E.Yu., Obarevich E.S., Gavrilova D.A., Besova N.S., Makiev G.G., Tryakin A.A., Evdokimov V.I., Pokataev I.A., Zhukova L.G., Danilova A.S., Fedyanin M.Yu., Cheporov S.V., Osipov M.A., Molodorina V.V. HER2-positive metastatic gastric / cardioesophageal junction cancer: a comparative retrospective analysis of trastuzumab maintenance therapy regimens. Medical alphabet. 2025;(33):7-12. (In Russ.) https://doi.org/10.33667/2078-5631-2025-33-7-12
Views:
156
JATS XML
Email this article 